Disclaimer
Some
of the compounds featured are experimental antiretroviral
agents. For prescribing and all other information please contact
the relevant manufacturer.
This
programme also discusses clinical development activities investigating
unapproved dosing schedules of currently registered antiretroviral
agents. Please refer to local prescribing information for
approved indications, dosing regimens and other relevant information.
The
views expressed are those of the presenters and are not necessarily
those of F.Hoffmann-La Roche Ltd. or MediTech Media Ltd
|